Articles From: Brinker International Board Declares Common Dividend to Bristow Group Announces Fiscal Year 2015 Third Quarter Earnings Release and Conference Call Schedule


DALLAS , Oct.
Sign-up for Brinker International Board Declares Common Dividend investment picks
2015/1/20
By Josh Beckerman Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers Operating Chief to Become CEO in May investment picks
2015/1/20
By Jonathan D.
Sign-up for Bristol-Myers Operating Chief to Become CEO in May -- 2nd Update investment picks
2015/1/20
By Josh Beckerman Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers Operating Chief to Become CEO in May -- Update investment picks
Bristol-Myers Squibb (BMY) reported Friday third-quarter net profit that rose to $721 million, or 43 cents a share, from $692 million, or 42 cents a share, in the year-earlier period.
Sign-up for Bristol-Myers profit slips, but tops expectations investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and the California Institute for Biomedical Research (Calibr) announced today they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration.
Sign-up for Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic Diseases investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). The Phase 1a/1b study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma.
Sign-up for Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) announced today a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299). The Phase 1/2 trial will evaluate the investigational combination of Opdivo and galunisertib as a potential treatment option for patients with advanced (metastatic and/or unresectable) glioblastoma, hepatocellular carcinoma and non-small cell lung cancer.
Sign-up for Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement.
Sign-up for Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement investment picks
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock of the corporation.
Sign-up for Bristol-Myers Squibb Announces Dividend investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab). Please see full Prescribing Information available at www.bms.com .
Sign-up for Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab) investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May 5.
Sign-up for Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and F-star Alpha Ltd.
Sign-up for Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy investment picks
2014/11/10
As America prepares to salute the nation’s military veterans for their service and sacrifice, the Bristol-Myers Squibb Foundation today marked Veterans Day by announcing more than $2 million in new grants to support three leading programs that help post-9/11 veterans and their families transition from military to civilian life.
Sign-up for Bristol-Myers Squibb Foundation Awards $2 Million in New Grants to Help Veterans and their Families Transition from Military to Civilian Life investment picks
The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations.
Sign-up for Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients with Hepatitis B and C in China and India investment picks
2014/12/1
The Bristol-Myers Squibb Foundation today marked World AIDS Day by announcing 12 new grants totaling $1.47 million that focus on strengthening community-based services in sub-Saharan Africa for adolescents and the elderly who are living with HIV and for HIV patients with comorbid female cancers or tuberculosis.
Sign-up for Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Million in New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries investment picks
By Angela Chen Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers Squibb jumps on Opdivo cancer drug test investment picks
Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers Squibb names Giovanni Caforio CEO, effective May 5 investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use.
Sign-up for Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C (HCV). The initial daclatasvir NDA submitted to the FDA focused on its use in combination with asunaprevir, an NS3/4A protease inhibitor.
Sign-up for Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today reported strong financial results for the third quarter of 2014, adjusted 2014 GAAP guidance and confirmed 2014 non-GAAP guidance.
Sign-up for Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions.
Sign-up for Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis investment picks
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015.
Sign-up for Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio.
Sign-up for Bristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland investment picks
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Credit Suisse Annual Health Care Conference on Tuesday, November 11, 2014 in Phoenix.
Sign-up for Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference investment picks
Bristol-Myers Squibb Company (NYSE:BMY) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, in San Francisco.
Sign-up for Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference investment picks
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA.
Sign-up for Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Brinker International Board Declares Common Dividend to Bristow Group Announces Fiscal Year 2015 Third Quarter Earnings Release and Conference Call Schedule
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent